Market News Call

Stocks To Watch: Novavax, Inc. (NASDAQ:NVAX), Baxalta Inc(NYSE:BXLT), Exelixis, Inc. (NASDAQ:EXEL)

Lakeway, NY — (MARKET NEWS CALL) — 19/02/2016—, an investment community with a special focus on updating investors with recent news on the U.S. stock market about the small and penny stocks, issues news alert on Novavax, Inc. (NASDAQ:NVAX), Baxalta Inc(NYSE:BXLT), Exelixis, Inc. (NASDAQ:EXEL).

Novavax, Inc. (NASDAQ:NVAX)’s shares jumped 0.21% to $4.86. The company on Feb. 5, 2016, announced that, in connection with Novavax’ previously announced initial offering of 3.75% Senior Convertible Notes due 2023 (the “Notes”), the initial purchasers have exercised in part their previously announced over-allotment option to purchase an additional $25 million aggregate principal amount of the Notes (the “Additional Notes”). The closing of the sale of the Additional Notes occurred on Feb. 5, 2016. Following the closing of the Additional Notes, Novavax has issued a total of $325 million aggregate principal amount of its 3.75% Senior Convertible Notes due 2023.

Should Investors Buy NVAX After The Recent Development? Find Out Here

Baxalta Inc(NYSE:BXLT)’s shares declined 0.71% to $39.12. The company, on Feb. 16, 2016, reported fourth-quarter profit of $95 million. The company said it had profit of 14 cents per share. Adjutsed earnings came to 57 cents per share. The results surpassed Wall Street expectations. The average estimate of analysts was for earnings of 56 cents per share. The company posted revenue of $1.76 billion in the period. For the year, the company reported profit of $956 million, or $1.40 per share. Revenue was reported as $6.15 billion.

Is BXLT Going To Rise or Fall After Today’s Price Action? Find Out Here

Exelixis, Inc. (NASDAQ:EXEL)’s shares fell 1.97% to $3.99. The company announced that its fourth quarter and full year 2015 financial results will be released on Feb. 29, 2016 after the markets close.

Can Traders Buy EXEL After The Solid Rally? Get Free Trend Analysis Here

Additionally, the company, on Feb. 1, 2016, announced positive overall survival (OS) results from METEOR, the phase 3 pivotal trial comparing cabozantinib to everolimus in 658 patients with advanced renal cell carcinoma (RCC) who have experienced disease progression following treatment with a VEGF receptor tyrosine kinase inhibitor (TKI).

About is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. also provides investors with trend analysis, detailed company profiles, and most importantly a much needed “informational edge” which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at


The assembled information disseminated by is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. does expect that investors will buy and sell securities based on information assembled and presented in PLEASE always do your own due diligence, and consult your financial advisor.

Tags: , , , ,

Comments are closed.